跳至主要内容
临床试验/NCT01898182
NCT01898182已完成4 期

A Single Arm, Phase IV, Open-Label, Split-Face Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Photoaging

Makati Medical Center4 个研究点 分布在 1 个国家目标入组 132 人开始时间: 2013年11月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
132
试验地点
4
主要终点
Skin Roughness

研究概览

简要总结

The purpose of the study is to evaluate the change in the severity and clinical signs of skin photoaging among Filipino patients using Kinerase cream (Kinetin 0.1%). This study will recruit 132 subjects from dermatological clinics in a tertiary hospital in the Philippines for a period of 3 months (12 weeks). Changes in severity will be documented using physician evaluation, self-evaluation, and through VISIA complexion analysis system.

详细描述

This study is a single-arm, open-label, split-face trial in subjects with mild to moderate photoaged facial skin. The study will enroll around 132 subjects from selected private dermatology clinics in a tertiary hospital in the Philippines.

Patients from selected private dermatology clinics of a tertiary hospital will be screened and recruited to participate. They will be provided a written consent form (Appendix I) before they will be included in the study.

Following enrollment, subjects will return for outpatient visits at weeks 4, 8, and 12 for assessment.

The whole study will be conducted from July 2013 to November 2013. The first month would involve recruitment of patients. Qualified patients will start the 12-week treatment period and will be asked to follow up every 4 weeks. The last two months would be for data analysis, interpretation and writing of the scientific report.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
盲法
None

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Filipino and Asian female subjects from private clinics of a tertiary hospital in the Philippines older than 35 years of age and less than 65 years of age.
  • Subjects with mild to moderate cutaneous photoaging as assessed by the investigator's assessment 6-point scale.
  • Subjects willing to sign an informed consent and adhere to all protocol requirements.

排除标准

  • Suspected porphyria, systemic or cutaneous lupus erythematosus, or any other photosensitizing disorder or drug-induced photosensitization
  • Chronic or recurring skin disease or disorder
  • Any active infectious skin disorder (Herpes simplex, molluscum contagiosum, and facial warts)
  • Skin cancer of the facial tissues
  • Any laser/IPL/ chemical peel in the 2 months preceding the screening visit
  • History of Isotretinoin use, 6 months prior to the screening disease
  • Topical tretinoin or adapalene in the 2 months prior to the screening visit
  • Used topical alpha-hydroxy acid skincare products in the month preceding the screening visit
  • On any anti-aging products and who wish to continue use of their products
  • Requiring concurrent treatment that would interfere with the study assessments
  • Pregnant or lactating females

结局指标

主要结局

Skin Roughness

时间窗: 12 weeks

Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12

Pigmentation

时间窗: 12 weeks

Also called Mottling or Blotchiness. This is measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12

Pores

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Fine wrinkles

时间窗: 12 weeks

Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12

Global Improvement in Cutaneous Photoaging

时间窗: 12 weeks

Measured using Physician Evaluation and Patient Self-Evaluation of severity of cutaneous photoaging at baseline week, weeks 4, 8, and 12

Wrinkles

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Texture

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Porphyrins

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Visual Spots

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

UV spots

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Brown Spots

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

Red Areas

时间窗: 12 weeks

Measured using VISIA Complexion Analysis System at baseline week, weeks 4 and 8.

次要结局

  • Erythema(12 weeks)
  • Burning(12 weeks)
  • Peeling(12 weeks)
  • Pruritus(12 weeks)
  • Dryness(12 weeks)
  • Edema(12 weeks)
  • Acne(12 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ma. Purita Paz-Lao, MD, FPDS

Chairman

Makati Medical Center

研究点 (4)

Loading locations...

相似试验